Keywords: Astellas, Cytori Thera, Regenerative medicines, Equity stake, Liver disease
Astellas takes equity stake in Cytori as part of regenerative medicines deal
Article | 08 December 2010
San Diego, USA-based Cytori Therapeutics (Nasdaq: CYTX) and Japan’s Astellas Pharma (4503: JP) have entered into a strategic equity ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
